Cover Image
市場調查報告書

西歐的搭配診斷市場

Western European Companion Diagnostics Market

出版商 Frost & Sullivan 商品編碼 304537
出版日期 內容資訊 英文 164 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
西歐的搭配診斷市場 Western European Companion Diagnostics Market
出版日期: 2014年05月23日 內容資訊: 英文 164 Pages
簡介

本報告提供西歐的搭配診斷市場相關調查、癌症相關市場區隔的議論、各癌症、疾病類型的試驗數的預測、各國的醫療費給付途徑分析、法規情形分析等。

本報告提供以下問題的答案。

  • 主要打入市場企業為何?在歐洲市場中市場參與企業的成長如何策略化?
  • 現在,使用搭配診斷的產品領域為何?
  • 支撐搭配診斷市場本質的經營模式為何?
  • 歐洲的搭配診斷形勢中存在的主要課題為何?
  • 隨時間流逝市場結構如何變化?收購的時機是否成熟?
  • 目前法規團體有多少支援?在各種地區他們完成的作用為何?

第1章 摘要整理

第2章 市場概要

  • 市場背景
  • 市場區隔
  • 整體市場展望
  • 未來的醫療趨勢定義

第3章 歐洲的法規概要

  • 法規概要:歐洲
  • 歐洲的未來的IVD法規
  • EMA所扮演的角色
  • 醫藥品標籤需要EMA的生物標記檢驗
  • FDA、CE標註比較
  • 美國、歐洲、中國的比較分析
  • 全球法規展望

第4章 競爭劇本

  • 新的市場機會
  • 目前市場參與企業的策略議論
  • 未滿足需求的議論

第5章 促進要素、阻礙要素:搭配診斷整體市場

  • 市場成長的促進要素
  • 市場成長的阻礙要素
  • 主要趨勢的市場影響

第6章 預測與趨勢:搭配診斷整體市場

  • 檢測
  • 歐洲的搭配診斷市場概要
  • 重要的市場特徵
  • 預測的前提條件
  • 搭配診斷整體市場:收益預測
  • 搭配診斷整體市場:各疾病的收益預測
  • 收益預測的議論
  • PEST分析

第7章 乳癌檢驗

  • 乳癌檢驗的收益預測
  • 乳癌檢驗的收益預測的議論

第8章 肺癌症篩檢

第9章 結腸直腸癌症、其他癌症的檢驗

第10章 感染疾病、CNS、心臟血管檢驗

第11章 競爭環境

  • 競爭環境
  • 產品分析
  • 主要的競爭企業
  • 市場佔有率:各層級
  • 合併、收購、聯盟評估
  • 搭配診斷的合作夥伴
  • 搭配診斷聯盟的治療領域
  • 搭配診斷聯盟的種類
  • 搭配診斷聯盟的全球有效半徑

第12章 歐洲的醫療費給付形勢

  • 簡介
  • 醫療費給付系統概要
  • 西歐整體CDx(搭配診斷)普及

第13章 德國:醫療費給付概要

  • 個人化醫療概要
  • 醫療費給付概要

第14章 法國:醫療費給付概要

  • 個人化醫療概要
  • 醫療費給付概要

第15章 英國:醫療費給付概要

  • 個人化醫療概要
  • 醫療費給付概要

第16章 義大利:醫療費給付概要

  • 個人化醫療概要
  • 醫療費給付概要

第17章 西班牙:醫療費給付概要

  • 個人化醫療概要
  • 醫療支付制度
  • 價格、醫療費給付

第18章 斯堪地那維亞各國:醫療費給付概要

  • 個人化醫療概要
  • 醫療費給付概要

第19章 荷比盧三國:醫療費給付概要

  • 荷比盧三國:個人化醫療概要
  • 荷蘭:個人化醫療概要
  • 荷蘭:醫療費給付概要
  • 比利時:個人化醫療概要
  • 比利時:醫療費給付概要

第20章 結論

  • 結論:3大預測
  • 免責聲明

第21章 附錄

目錄
Product Code: NCF9-01-00-00-00

Regulatory Hurdles and LDTs Stall the Global and European Market for Companion Diagnostics

The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. The forecasts are based on test volumes for these cancers and disease types. Effective analysis of the reimbursement pathway in Germany, the United Kingdom, France, Italy, Spain, Scandinavia, and Benelux, coupled with regulatory approval in Europe, is discussed. A comparative assessment of regulatory scenarios has been performed to assess easy-target markets.

Key Questions This Study Will Answer

  • Who are the key market participants? How are they strategizing their growth in the European market?
  • In what current product areas are companion diagnostics being used? Which disease area is expected to experience the most growth in the future?
  • What are the different business models that exist and support the nature of the companion diagnostics market?
  • What are the key challenges that exist in the European companion diagnostics landscape?
  • How will the structure of the market change over time? Is it ripe for acquisitions?
  • How supportive are the current regulatory bodies? What impacts do they have in various regions?

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. Scope and Segmentation
  • 4. Key Questions This Study Will Answer
  • 5. Measurements
  • 6. CEO's Perspective
  • 7. Key Companies to Watch
  • 8. Executive Summary-3 Big Predictions

2. MARKET OVERVIEW

Market Overview

  • 1. Market Background
  • 2. Market Background (continued)
  • 3. Market Background (continued)
  • 4. Market Background (continued)
  • 5. Market Segmentation
  • 6. Overall Market Perspective
  • 7. Defining Healthcare Trends in the Future

3. EUROPEAN REGULATORY OVERVIEW

European Regulatory Overview

  • 1. Regulatory Overview-Europe
  • 2. Regulatory Overview-Europe (continued)
  • 3. Future IVD Regulation in Europe
  • 4. Role of EMA
  • 5. Drug Labels Requiring Biomarker Testing by the EMA
  • 6. Comparison of FDA and CE Marking
  • 7. Comparative Analysis of the United States, Europe, and China
  • 8. Global Regulatory Outlook

4. COMPETITIVE PLAYBOOK

Competitive Playbook

  • 1. New Market Opportunities
  • 2. New Market Opportunities (continued)
  • 3. New Market Opportunities (continued)
  • 4. Current Participant Strategies Discussion
  • 5. Current Participant Strategies Discussion (continued)
  • 6. Unmet Needs Discussion
  • 7. Unmet Needs Discussion (continued)

5. DRIVERS AND RESTRAINTS-TOTAL COMPANION DIAGNOSTICS MARKET

Drivers and Restraints-Total Companion Diagnostics Market

  • 1. Market Drivers
  • 2. Market Restraints
  • 3. Market Impact of Top Trends

6. FORECASTS AND TRENDS-TOTAL COMPANION DIAGNOSTICS MARKET

Forecasts and Trends-Total Companion Diagnostics Market

  • 1. Measurements
  • 2. Snapshot of the European Companion Diagnostics Market
  • 3. Important Market Characteristics
  • 4. Forecast Assumptions
  • 5. Total Companion Diagnostics Market-Revenue Forecast
  • 6. Total Companion Diagnostics Market-Revenue Forecast by Disease Focus
  • 7. Revenue Forecast Discussion
  • 8. Revenue Forecast Discussion (continued)
  • 9. PEST Analysis
  • 10. PEST Analysis (continued)

7. BREAST CANCER TESTING

Breast Cancer Testing

  • 1. Revenue Forecast for Breast Cancer Testing
  • 2. Revenue Forecast for Breast Cancer Testing Discussion

8. LUNG CANCER TESTING

Lung Cancer Testing

  • 1. Revenue Forecast for Lung Cancer Testing
  • 2. Revenue Forecast for Lung Cancer Testing Discussion

9. COLORECTAL CANCER AND OTHER CANCERS TESTING

Colorectal Cancer and Other Cancers Testing

  • 1. Revenue Forecast for Colorectal Cancer Testing
  • 2. Revenue Forecast for Other Cancers Testing
  • 3. Revenue Forecast for Colorectal Cancer and Other Cancers Testing Discussion

10. INFECTIOUS DISEASE, CNS, AND CARDIOVASCULAR TESTING

Infectious Disease, CNS, and Cardiovascular Testing

  • 1. Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing
  • 2. Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing Discussion
  • 3. Revenue Forecast Discussion
  • 4. Revenue Forecast Discussion (continued)

11. COMPETITIVE ENVIRONMENT

Competitive Environment

  • 1. Competitive Environment
  • 2. Competitive Environment (continued)
  • 3. Product Analysis
  • 4. Product Analysis (continued)
  • 5. Top Competitors
  • 6. Top Competitors (continued)
  • 7. Market Share by Tier
  • 8. Market Share by Tier (continued)
  • 9. Merger, Acquisition, and Partnership Assessment
  • 10. Merger, Acquisition, and Partnership Assessment (continued)
  • 11. Companion Diagnostic Partners
  • 12. Companion Diagnostic Partners (continued)
  • 13. Therapy Areas for Companion Diagnostic Partnerships
  • 14. Types of Companion Diagnostic Partnerships
  • 15. Global Reach of Companion Diagnostic Partnership

12. EUROPEAN REIMBURSEMENT LANDSCAPE

European Reimbursement Landscape

  • 1. Introduction
  • 2. Reimbursement Systems Overview
  • 3. CDx Penetration Across Western Europe

13. GERMANY-REIMBURSEMENT OVERVIEW

Germany-Reimbursement Overview

  • 1. Germany-Personalized Medicine Overview
  • 2. Germany-Personalized Medicine Overview (continued)
  • 3. Germany-Overview of Reimbursement

14. FRANCE-REIMBURSEMENT OVERVIEW

France-Reimbursement Overview

  • 1. France-Personalized Medicine Overview
  • 2. France-Personalized Medicine Overview (continued)
  • 3. France-Overview of Reimbursement
  • 4. France-Overview of Reimbursement (continued)

15. THE UNITED KINGDOM-REIMBURSEMENT OVERVIEW

The United Kingdom-Reimbursement Overview

  • 1. The United Kingdom-Personalized Medicine Overview
  • 2. The United Kingdom-Personalized Medicine Overview (continued)
  • 3. The United Kingdom-Overview of Reimbursement

16. ITALY-REIMBURSEMENT OVERVIEW

Italy-Reimbursement Overview

  • 1. Italy-Personalized Medicine Overview
  • 2. Italy-Personalized Medicine Overview (continued)
  • 3. Italy-Personalized Medicine Overview (continued)
  • 4. Italy-Overview of Reimbursement
  • 5. Italy-Overview of Reimbursement (continued)

17. SPAIN-REIMBURSEMENT OVERVIEW

Spain-Reimbursement Overview

  • 1. Spain-Personalized Medicine Overview
  • 2. Spain-Healthcare Payment System
  • 3. Spain-Pricing and Reimbursement
  • 4. Spain-Pricing and Reimbursement (continued)

18. SCANDINAVIA-REIMBURSEMENT OVERVIEW

Scandinavia-Reimbursement Overview

  • 1. Scandinavia-Personalized Medicine Overview
  • 2. Scandinavia-Personalized Medicine Overview (continued)
  • 3. Scandinavia-Reimbursement Overview
  • 4. Scandinavia-Reimbursement Overview (continued)

19. BENELUX-REIMBURSEMENT OVERVIEW

Benelux-Reimbursement Overview

  • 1. Benelux-Personalized Medicine Overview
  • 2. The Netherlands-Personalized Medicine Overview
  • 3. The Netherlands-Reimbursement Overview
  • 4. The Netherlands-Reimbursement Overview (continued)
  • 5. Belgium-Personalized Medicine Overview
  • 6. Belgium-Reimbursement Overview
  • 7. Belgium-Reimbursement Overview (continued)

20. THE LAST WORD

The Last Word

  • 1. The Last Word-3 Big Predictions
  • 2. The Last Word-Discussion
  • 3. The Last Word-Discussion (continued)
  • 4. The Last Word-Discussion (continued)
  • 5. The Last Word-Discussion (continued)
  • 6. The Last Word-Discussion (continued)
  • 7. Legal Disclaimer

21. APPENDIX

Appendix

  • 1. Europe-Drivers Explained
  • 2. Europe-Drivers Explained (continued)
  • 3. Europe-Drivers Explained (continued)
  • 4. Europe-Restraints Explained
  • 5. Europe-Restraints Explained (continued)
  • 6. Europe-Restraints Explained (continued)
  • 7. Europe-Restraints Explained (continued)
  • 8. Europe-Restraints Explained (continued)
  • 9. Europe-Restraints Explained (continued)
  • 10. Europe-Restraints Explained (continued)
  • 11. Europe-Restraints Explained (continued)
  • 12. Decision Support Database
  • 13. Decision Support Database (continued)
  • 14. Decision Support Database (continued)
  • 15. Decision Support Database (continued)
  • 16. Decision Support Database (continued)
  • 17. Associated Multimedia
  • 18. Methodology
  • 19. Learn More-Next Steps
Back to Top